Health-Related Quality of Life in Disease-Modifying Antirheumatic Drug–Treated Adults With Juvenile Idiopathic Arthritis Compared to Rheumatoid Arthritis and the General Population

I. Bardan, MD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
T. Uhlig, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
J. Sexton, MSc, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
T. K. Kvien, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
G. Bakland, MD, PhD, Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway.
P. Mielnik, MD, PhD, Section for Rheumatology, Helse Førde, Førde, Norway.
Y. Hu, MD, PhD, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
Ø. Molberg, MD, PhD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
A.B. Aga, MD, PhD, Department of Rheumatology, Oslo University Hospital, Rikshospitalet; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.

A.B. Aga and E.K. Kristianslund contributed equally to this work as co-senior authors.
ACKNOWLEDGMENT: This work is the result of a cooperation between Oslo University Hospital (Oslo, Norway) and the REMEDY center at Diakonhjemmet Hospital (Oslo, Norway).
CONTRIBUTIONS: IB: conceptualization; formal analysis; funding acquisition; investigation; methodology; project administration; visualisation; writing - original draft; writing - review & editing. TU: conceptualization; methodology; resources; supervision; writing - review & editing. JS: data curation; formal analysis; methodology; validation; writing - review & editing. TKK: conseptualization; investigation; resources; writing - review & editing. GB, PM, YH: investigation; resources; writing - review & editing. ØM: conceptualization; supervision; writing - review & editing. ABA: conceptualization; funding acquisition; supervision; writing - review & editing. EKK: concecptualization; investigation; resources; supervision; writing - review & editing.
FUNDING: This work was supported by the research fund of the foundation Norsk Revmatikerforbund and senior doctor Jan A. Pahle's endowment.
COMPETING INTERESTS: TKK received grants from AbbVie, BMS, Galapagos, Novartis, Pfizer, and UCB; consulting fees from AbbVie, Gilead, Janssen, Novartis, Pfizer, Sandoz, and UCB; speaker's fees from Grünenthal, Janssen, and Sandoz; and participated on a Data Safety Monitoring Board for AbbVie. GB received a speaker's fee from Johnson & Johnson. YH received a speaker's fee from Boehringer Ingelheim. ABA received speaker's fees from AbbVie, Lilly, Novartis, and Pfizer. The remaining authors declare no conflicts of interest relevant to this article.
ETHICS AND PATIENT CONSENT: The study complies with the Declaration of Helsinki. Patients gave written informed consent prior to inclusion. Ethical approval is provided by the East- Norwegian Regional Committee for Medical and Health Research Ethics (ethical approval no. 2011/1339). Data storage approval is provided by the Data Inspectorate.
SUPPLEMENTARY DATA: Supplementary material accompanies the online version of this article.
Accepted for publication August 6, 2025.